rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Andrew Craig Miller

Director

Company insider

Files Form 4 as: Director, Alto Neuroscience; Director, Kyverna Therapeutics; President of R&D, Karuna Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
156
Buys
0
Sells
32
Bought
$0
Sold
$44.5M
Companies
3
Companies where not an officer
2
First trade
14 Feb 2020
Last trade
27 May 2026
Last filed
29 May 2026

Companies traded

Where they are an officer
Karuna TherapeuticsOfficer · last 18 Mar 20240 buys · 32 sells
Everywhere else they filed: board seats, 10% stakes, other companies
ANRO Alto NeuroscienceDirector · Biotechnology · last 27 May 20260 buys · 0 sells
KYTX Kyverna TherapeuticsDirector · Biotechnology · last 24 Feb 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
27 May 2026filed 29 May 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A—26,000 at $0.00filing
27 May 2026filed 29 May 2026ANRO Alto Neuroscienceoption or derivative · BiotechnologySEC FORM 4 Code A—26,000 at $0.00filing
24 Feb 2026filed 4 Mar 2026KYTX Kyverna TherapeuticsBiotechnologySEC FORM 4 Code A—11,006 at $0.00filing
24 Feb 2026filed 4 Mar 2026KYTX Kyverna Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—42,945 at $0.00filing
24 Feb 2026filed 4 Mar 2026KYTX Kyverna Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—42,945 at $0.00filing
24 Feb 2026filed 4 Mar 2026KYTX Kyverna TherapeuticsBiotechnologySEC FORM 4 Code A—11,006 at $0.00filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$5.2M15,855 at $330.00filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$15.6M47,817 at $327.08filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$3.7M11,578 at $322.73filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$74.4M231,992 at $320.80filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$16.1M70,000 at $230.28filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$13.3M66,900 at $198.36filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$16.0M73,250 at $218.03filing
18 Mar 2024filed 18 Mar 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code D$3.6M25,100 at $142.74filing
18 Mar 2024filed 18 Mar 2024Karuna TherapeuticsSEC FORM 4 Code D$4.6M13,977 at $330.00filing
18 Mar 2024filed 18 Mar 2024Karuna TherapeuticsSEC FORM 4 Code D$3.1M9,412 at $330.00filing
13 Feb 2024filed 15 Feb 2024Karuna Therapeuticsoption or derivativeSEC FORM 4 Code A—15,855 at $0.00filing
9 Feb 2024filed 12 Feb 2024Karuna TherapeuticsSEC FORM 4 Code F$321K1,011 at $317.14filing
20 Apr 2023filed 20 Apr 2023Karuna Therapeuticsoption or derivativeSEC FORM 4 Code M—8,500 at $0.00filing
20 Apr 2023filed 20 Apr 2023Karuna TherapeuticsSEC FORM 4 Code M$78K8,500 at $9.20filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed32

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.